AIP
BLTE

Arrowpoint Investment Partners’s Belite Bio BLTE Stock Holding History

Arrowpoint Investment Partners’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Sell
2,008
-3,996
-67% -$612K 0.07% 91
2026
Q1 		$957K Buy
6,004
+2,955
+97% +$497K 0.85% 24
2025
Q4 		$488K Buy
+3,049
New +$361K 0.07% 74

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowpoint Investment Partners's BLTE Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Belite Bio (BLTE) stake by 67% in Q2 2026, selling an estimated $612K and leaving 2,008 shares worth $309K. The position accounts for 0.07% of the portfolio, ranked #91.

Arrowpoint Investment Partners first reported a position in BLTE in Q4 2025 and has held it in 3 quarters since. The position peaked at $957K in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Arrowpoint Investment Partners held 2,008 shares of Belite Bio worth $309K as of Q2 2026.
  • Arrowpoint Investment Partners sold 3,996 Belite Bio shares in Q2 2026, an estimated $612K.
  • Belite Bio made up 0.07% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #91 holding.
  • Arrowpoint Investment Partners first reported a position in Belite Bio in Q4 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Belite Bio position peaked at $957K in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.